SCHEMBL4698765

SCHEMBL4698765

Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1Nc1ncnc2c1cnn2C

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 13/20 0.61
BTK Q06187 3/20 0.61
MAPK14 Q16539 2/20 0.61
KDR P35968 2/20 0.61
ESYT2 A0FGR8 1/20 0.61
PLEKHG3 A1L390 1/20 0.61
NBAS A2RRP1 1/20 0.61
CNOT1 A5YKK6 1/20 0.61
TBKBP1 A7MCY6 1/20 0.61
MYO1G B0I1T2 1/20 0.61
AGPS O00116 1/20 0.61
MYO1F O00160 1/20 0.61
SNAP23 O00161 1/20 0.61
AP3B1 O00203 1/20 0.61
PSMD12 O00232 1/20 0.61
BMPR1B O00238 1/20 0.61
PGRMC1 O00264 1/20 0.61
CLIC1 O00299 1/20 0.61
CDC7 O00311 1/20 0.61
PDHX O00330 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4701699 0.93 BRAF (0.70) BRAFBTKMAPK14KDRESYT2
SCHEMBL4787068 0.90 BRAF (0.57) BRAFBTKKDRABL1LMNA
SCHEMBL4696327 0.88 MAPK14 (0.61) BRAFBTKMAPK14KDRESYT2
SCHEMBL4917626 0.88 BRAF (0.58) BRAFBTKKDRABL1CSF1R
SCHEMBL4701650 0.87 MAPK14 (0.59) BRAFMAPK14KDRLMNALCK
SCHEMBL4699789 0.86 LMNA (0.59) BRAFBTKMAPK14KDRLMNA
SCHEMBL4751792 0.86 MAPK14 (0.58) BRAFMAPK14KDRLMNALCK
SCHEMBL4699063 0.86 BRAF (0.55) BRAFBTKKDRABL1INSR
SCHEMBL4696070 0.86 BRAF (0.57) BRAFCSF1RKIT
SCHEMBL4698202 0.86 MAPK14 (0.63) BRAFBTKMAPK14KDRESYT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1963327-A1 3-(SUBSTITUTED AMINO)-PYRAZOLO[3,4-d]PYRIMIDINES AS EPHB AND VEGFR2 KINASE INHIBITORS Novartis AG (CH) 2008-09-03 EP claimed
WO-2007062805-A1 3-(SUBSTITUTED AMINO)-PYRAZOLO[3,4-d]PYRIMIDINES AS EPHB AND VEGFR2 KINASE INHIBITORS NOVARTIS AG (CH) 2007-06-07 WO claimed
US-20080275054-A1 3-(Substituted Amino)-Pyrazolo[3, 4-D]Pyrimidines as Ephb and Vegfr2 Kinase Inhibitors HOLZER PHILIPP 2008-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275054-A1 3-(Substituted Amino)-Pyrazolo[3, 4-D]Pyrimidines as Ephb and Vegfr2 Kinase Inhibitors EPHB3, EPHB2, EPHB1 BRAF 42/4885BTK 214/4885MAPK14 252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.